Objective

Rising global prevalence of gestational diabetes mellitus (GDM)¹

UK NICE: selective GDM screening using OGTT for high-risk women²

FIGO: recommends universal GDM screening³

Multiple GDM risk prediction tools exist, but limited clinical adoption⁴⁻⁷

Primary aim: Identify risk factors for GDM across four countries (see Table 1)

Secondary aim: Assess sensitivity and specificity of NICE criteria for GDM diagnosis

Design

Retrospective cohort study 

Secondary analysis of ‘Impact Diabetes Bump2Baby and Me’ clinical trial

Settings: Australia, Ireland, Spain and the UK⁸

Population: Pregnant women from ~12 weeks' gestation to two years postpartum.

GDM: Positive OGTT between 24-28 weeks using The International Association of Diabetes and Pregnancy Study Groups criteria⁹

Limitations

Small sample size 

Study population pre-selected as high-risk using the Monash GDM Screening Tool⁷

Differences between study and general populations e.g. age, employment, education 

Missing data, despite use of multiple imputation

Clinical trial involved health management interventions